Enlivex Therapeutics (ENLV) Stock Chart & Stock Price History $1.27 -0.01 (-0.39%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enlivex Therapeutics Stock Price Performance The Enlivex Therapeutics (ENLV) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 13.85%, with a year-to-date return of 8.97%. In the past month, the stock has increased 40.88%, reflecting recent market activity. As of the latest close, Enlivex Therapeutics traded at $1.28 with a market cap of $30.27 million and volume of 107,518 shares. Five years ago, the stock traded at $5.01, representing a 74.55% decrease over that period. At the time, it had a market cap of $67.28 million and a volume of 210,400 shares. Receive ENLV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.92%1 Month Performance+40.88%3 Month Performance+43.87%Year-To-Date Performance+8.97%1 Year Performance-13.85%5 Year Performance-74.55% ENLV Stock Chart for Monday, July, 14, 2025 ENLV Chart by TradingView Enlivex Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/11/2025$1.34$1.28-4.48%$1.36$1.23107,518 shs$30.27 million07/10/2025$1.30$1.34+3.08%$1.36$1.26241,459 shs$31.69 million07/09/2025$1.18$1.30+10.17%$1.38$1.18319,305 shs$30.75 million07/08/2025$1.21$1.18-2.48%$1.20$1.1462,809 shs$27.91 million07/07/2025$1.18$1.21+2.98%$1.22$1.19100,617 shs$28.62 million07/04/2025$1.18$1.18$1.21$1.15141,087 shs$27.79 million07/03/2025$1.13$1.18+3.98%$1.21$1.15141,087 shs$27.79 million07/02/2025$1.12$1.13+0.89%$1.16$1.1133,878 shs$26.73 million07/01/2025$1.12$1.12$1.16$1.1154,537 shs$26.49 million06/30/2025$1.20$1.12-6.67%$1.23$1.11196,647 shs$26.49 million Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/27/2025$1.21$1.20-0.83%$1.24$1.1568,117 shs$28.38 million06/26/2025$1.26$1.21-3.97%$1.27$1.1867,240 shs$28.62 million06/25/2025$1.19$1.26+5.88%$1.30$1.15208,906 shs$29.80 million06/24/2025$1.16$1.19+2.59%$1.27$1.15237,872 shs$28.14 million06/23/2025$1.09$1.16+6.42%$1.22$1.11228,887 shs$27.44 million06/20/2025$1.05$1.09+4.31%$1.17$1.03139,267 shs$25.78 million06/19/2025$1.05$1.05$1.08$1.0093,685 shs$24.71 million06/18/2025$1.03$1.05+1.46%$1.08$1.0093,685 shs$24.72 million06/17/2025$1.03$1.03$1.06$0.9938,620 shs$24.36 million06/16/2025$0.91$1.03+13.81%$1.07$0.93289,148 shs$24.36 million06/13/2025$0.94$0.91-3.72%$0.92$0.9021,988 shs$21.40 million Related Companies TARA Stock Chart ATOS Stock Chart HURA Stock Chart PROC Stock Chart CCCC Stock Chart ANIX Stock Chart MIST Stock Chart MCRB Stock Chart HLVX Stock Chart JSPR Stock Chart Receive ENLV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ENLV) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
